Detalhe da pesquisa
1.
Systematic discovery of mutation-directed neo-protein-protein interactions in cancer.
Cell
; 185(11): 1974-1985.e12, 2022 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35512704
2.
Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice.
CA Cancer J Clin
; 73(3): 275-285, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36627265
3.
Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.
Mol Cell
; 81(18): 3833-3847.e11, 2021 09 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34289383
4.
γ-6-Phosphogluconolactone, a Byproduct of the Oxidative Pentose Phosphate Pathway, Contributes to AMPK Activation through Inhibition of PP2A.
Mol Cell
; 76(6): 857-871.e9, 2019 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31586547
5.
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
N Engl J Med
; 389(11): 1009-1022, 2023 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646702
6.
The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells.
Mol Cell
; 69(6): 923-937.e8, 2018 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29547721
7.
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
N Engl J Med
; 387(2): 132-147, 2022 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35660812
8.
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
N Engl J Med
; 384(8): 705-716, 2021 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33626253
9.
Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth.
Mol Cell
; 64(5): 859-874, 2016 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27867011
10.
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Cancer
; 129(23): 3746-3760, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37622738
11.
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Blood
; 137(26): 3616-3628, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33763699
12.
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression.
Blood
; 137(26): 3604-3615, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33649772
13.
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma.
Haematologica
; 108(11): 2894-2912, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37608773
14.
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling.
Mol Cell
; 59(3): 345-358, 2015 Aug 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26145173
15.
Novel approaches to the treatment of multiple myeloma.
Clin Adv Hematol Oncol
; 21(5): 247-256, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37145495
16.
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
N Engl J Med
; 381(8): 727-738, 2019 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31433920
17.
Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex.
Mol Cell
; 53(4): 534-48, 2014 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-24486017
18.
Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth.
Mol Cell
; 55(4): 552-65, 2014 Aug 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-25042803
19.
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.
Lancet Oncol
; 22(1): 142-154, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33301738
20.
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
Lancet Oncol
; 22(3): e105-e118, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33662288